Novira Receives $23 Million To Develop New Antivirals
This article was originally published in The Pink Sheet Daily
Executive Summary
Previously supported by angels and seed-stage investors, the Philadelphia-area start-up has turned to 5AM Ventures and Canaan Partners for a Series A round that will support development of HBV and HIV drug candidates.